Annual report pursuant to Section 13 and 15(d)

Collaboration and License Agreements - Additional Information (Detail)

v3.21.1
Collaboration and License Agreements - Additional Information (Detail)
1 Months Ended 12 Months Ended
Jun. 30, 2006
Jun. 30, 1998
USD ($)
Dec. 31, 2020
USD ($)
Agreement
Dec. 31, 2019
USD ($)
Janssen Pharmaceutical NV [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Accrued royalties     $ 0 $ 0
Janssen Pharmaceutical NV [Member] | Maximum [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Percentage of royalty on net sales 8.00%      
Janssen Pharmaceuticals, Inc. [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Number of development and license agreements | Agreement     2  
DiaTex, Inc. [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Royalty payment     $ 0 0
Monthly license fees   $ 2,000    
Potential future development payments   $ 800,000    
Development payment     $ 0 $ 0